Don't Jump to Spiriva First-Line for Mild COPD
New evidence will spark controversy over how to treat COPD patients with MILD disease.
About seven in 10 COPD patients have early disease with minimal symptoms. But meds are usually studied in moderate to severe COPD.
Now evidence suggests that Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA), may be beneficial for mild COPD.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote